- Medical devices
Circulating Tumor Cells (CTC) Market – Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Report format:PDF+Excel |Report ID:SR112023A6316
- report description
- table of contents
- Request Sample
The global circulating tumor cell (CTC) market size has reached USD 10.7 billion by 2022. Looking ahead, IMARC Group expects the market to reach USD 20.0 billion by 2028, showing an increasing growth rate (CAGR) of 10.2% during 2023-2028.
Circulating tumor cells (CTCs) are cancer cells that break away from the primary tumor and appear in the circulatory system as single units or clusters. They have different biological phenotypes, such as epithelial, mesenchymal and mixed epithelial-mesenchymal. Levels of CTC in a patient's blood may allow early detection of cancer and act as a prognostic indicator. Because they are found in minimal numbers, various technologies are used for CTC isolation, enrichment, and detection, including immunocapture, size-based sorting, density-based sorting, and microscopy. It also has a wide range of applications in liquid biopsy, cancer research, drug development and clinical biomarkers.
Circulating tumor cells (CTC) market trends:
The increasing prevalence of cancer due to genetic diseases, increasing alcohol consumption and rapid changes in lifestyle are the main factors driving the growth of the market. CTC helps in the early identification and real-time control of lung, breast, digestive tract and prostate cancer. In line with this, the increasing use of CTC in the detection of metastases in patients and preclinical studies of new anticancer drugs is favoring market growth. In addition, the growing demand for minimally invasive (MI) diagnostic procedures and the widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are giving considerable impetus to market growth. Furthermore, the introduction of nanotechnology to improve the sensitivity and efficiency of CTC isolation and detection is driving the market growth. Furthermore, the increasing use in medical research to develop cell culture models fordrug screening, disease modeling, genome editing and tumor immunity are creating a positive outlook for the market. Furthermore, the growing awareness among healthcare professionals and patients about the importance of early cancer diagnosis is positively influencing market growth. Other factors, including rapid advances in biomedical imaging and bioengineering technology, extensive research and development (R&D) activities, and growing demand for preventive medicine and complementary diagnostics, are expected to drive market growth.
Main market segments:
The IMARC Group provides analysis of key trends in each sub-segment of global circulating tumor cells (CTCs) market report along with 2023-2028 global, regional and country forecasts. Our report has categorized the market based on technology, application, product, sample and end-user.
Division by technology:
- CTC detection and enrichment method
- Direct CTC detection methods
- CTC analysis
Breakdown by application:
- Clinical/liquid biopsy
- risk assessment
- Detection and monitoring
- Cancer stem cell research and tumorigenesis
- Drug/Therapy Development
- Kits and Reagents
- blood collection tubes
- Devices and Systems
Breakdown by sample:
- bone marrow
- Other body fluids
Breakdown by end user:
- Hospitals and clinics
- Academic and research institutes
- Diagnostic Centers
Division by region:
- North America
- asian pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The industry competitive landscape has also been examined along with profiles of key players, which are BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics and Stemcell Technologies.
|Base Year of Analysis||2022|
|Units||billion US dollars|
|segment coverage||technology, application, product, sample, end user, region|
|Region covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|covered countries||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|companies covered||BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics e Stemcell Technologies|
|customization scope||10% free customization|
|Inform Price and Purchase Option||Single User License: $2,499|
Five-user license: $3,499
Enterprise License: $4499
|Post-sales analyst support||10-12 weeks|
|Delivery format||PDF and Excel via Email (We can also provide the editable version of the report in PPT/Word format upon special request)|
Key questions answered in this report
The global Circulating Tumor Cells (CTC) market was valued at $10.7 billion in 2022.
We expect the global Circulating Tumor Cells (CTC) market to grow at a CAGR of 10.2% during 2023-2028.
The increasing adoption of Circulating Tumor Cells (CTCs) in liquid biopsy, cancer research, drug development, clinical biomarkers, etc., is mainly driving the global Circulating Tumor Cells (CTCs) market.
The sudden outbreak of the COVID-19 pandemic has led to the postponement of elective cancer treatment procedures to reduce the risk of coronavirus infection during hospital visits or interaction with medical equipment, which has had a negative impact on the global Circulating Tumor Cells (CTC) market. ). ).
On the basis of technology, the global circulating tumor cell (CTC) market has been segmented into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. Among these, the CTC detection and enrichment method currently holds the largest share of the global market.
Based on application, the global Circulating Tumor Cells (CTC) market can be split into clinical/liquid biopsy and research. Currently, search represents the largest share of the market.
On a product basis, the global Circulating Tumor Cells (CTC) market has been segregated into Kits & Reagents, Blood Collection Tubes, and Devices & Systems, with Devices & Systems currently exhibiting clear dominance of the market.
According to the sample, the global Circulating Tumor Cells (CTC) market can be divided into Blood, Bone Marrow and Other Body Fluids. Currently, blood holds the largest share of the total market.
Regionally, the market has been categorized into North America, Asia Pacific, Europe, Latin America and the Middle East and Africa, where North America currently dominates the global market.
Some of the key players in the Circulating Tumor Cells (CTC) market include BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V , Rarecells Diagnostics and Stemcell Technologies.
Need more help?
- Talk to our experienced analysts to learn about current market scenarios.
- Add additional segments and countries to customize the report to your needs.
- Gain an unparalleled competitive advantage in your domain by understanding how to use the report and positively impact your operations and revenue.
- For further assistance, contact our analysts.
- To call
- Request Sample
Select license type
Consult before buying
talk to an analyst
Benefits of Customization
Customize this investigation
Triangle with your data
Get data according to its format and definition
Get a deeper dive into a specific application, geography, customer or competitor
Any level of customization
IMARC facilitated the whole process. Everyone I spoke to via email was friendly, easy to deal with, kept their promises regarding delivery times, and was solution focused. From the first contact I appreciated the professionalism shown by the entire IMARC team. I recommend IMARC to anyone who needs timely and accessible information and advice. My experience with IMARC was excellent and I cannot complain.
The IMARC team was very reactive and flexible regarding our requests. An overall very good experience. We are satisfied with the work that IMARC has done, very complete and detailed. It contributed to our business needs and provided the market visibility we needed.
We are very happy with the collaboration between IMARC and Colruyt. Not only were their prices competitive, IMARC was also very quick to understand the scope and our needs for this project. Although it was not an easy task, conducting market research during the COVID-19 pandemic was able to provide us with the necessary information. The IMARC team was very easy to work with and they showed us that they would go the extra mile if we needed anything extra.
The last project executed by your team was in line with our expectations. We would also like to partner with you for more assignments this year. Congratulations to your team.
We would be happy to contact IMARC again if we need market research/consultancy/consumer research or any associated services. Overall, the experience was good and the data points were quite useful.
The market study numbers were very close to our assumed numbers. The presentation of the study was organized and easy to analyze. The requested study details were completed. My overall experience with the IMARC team was satisfactory.
The total cost of services was within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to get the information I needed.
My questions and concerns were answered to my satisfaction. Service costs were within our expectations. My overall experience with the IMARC team was very good.
I agree that the report was delivered on time and met the main objectives of the work. We had some content discussions, adjustments were made quickly and accurately. Response time was minimal in each case. Very good. You have a satisfied customer.
We will be happy to contact IMARC for more market reports in the future. The account sales manager's response was very good. Thank you for the timely follow-ups and support after purchasing the equipment. My overall experience with IMARC was good.
IMARC was a good solution for data points that we really needed and couldn't find anywhere else. The team was easy to work with, quick to respond, and flexible to our customization requests.